Relation Therapeutics vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Relation Therapeutics uses its Lab-in-the-Loop AI platform to discover novel drug targets; secured a $1.7B multi-program Novartis collaboration and a $200M+ GSK partnership; raised $26M additional funding from NVIDIA Ventures in December 2025.
About
Relation Therapeutics is a UK-based clinical-stage biotechnology company that integrates artificial intelligence with experimental biology to discover novel therapeutic targets for diseases with significant unmet medical need. Its proprietary Lab-in-the-Loop platform combines machine learning with patient-derived single-cell multi-omics data, functional assays, and human genetics to identify causal genes and validate novel drug targets — moving beyond correlative genomics to experimental confirmation. The company''s initial therapeutic focus is osteoporosis, with additional programs in immunology, metabolic disease, and fibrosis.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Relation Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.